glp 1 gip receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology GLP-1 and GIP receptor signaling

However, its best to avoid pairing it with strong acids or oxidizing agents that may destabilize the peptide

Epidemiological studies have demonstrated a correlation between hyperglycemia and the severity of cardiovascular dysfunction and mortality in patients with DM [3, 4]

The current GLP-1 medications list includes semaglutide (Ozempic, Wegovy, Rybelsus, and an oral Wegovy pill), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon BCise), and lixisenatide (Adlyxin)

Study Design The study protocol was reviewed and approved by the Scientific Council of the General Hospital of Athens, Hippocratio (11888/24-6-2009) and it was conducted according to the principles of the Declaration of Helsinki of 1975 as revised in 2013